KPL3,520.00

Kwality Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
Comp Set
In ₹ Crore except Per Share
Latest Annual
KPL
FY24
BPLPHARMA
FY23
JENBURPH
FY26
MAKERSL
FY26
Peer
Median
Valuation — at last close
P/E37.02×37.02×
Growth
Revenue CAGR 3Y7.26%5.77%6.51%
Revenue CAGR 5Y9.07%1.55%5.31%
Net Income CAGR 3Y12.18%12.18%
Profitability
EBITDA Margin21.69%9.80%23.81%1.45%9.80% +121%
Net Income Margin11.16%20.59%-3.42%11.16%
Return on Common Equity12.74%-3.16%4.79%
Return on Capital Employed19.18%
Return on Assets7.90%15.37%-2.34%7.90%
Credit & Quality
Total Debt/Equity0.43×0.04×0.05×0.04× +856%
Interest Coverage4.54×7.10×-3.91×1.59× +185%
Scale — latest FY
Revenue / Total Income₹307 Cr₹218 Cr₹169 Cr₹50.3 Cr₹169 Cr +82%
Net Income₹24.3 Cr₹34.7 Cr−₹1.7 Cr₹24.3 Cr
Total Assets₹398 Cr₹308 Cr₹226 Cr₹73.5 Cr₹226 Cr +76%
EPS₹42.14₹-2.91₹19.62
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.